Symeres, a Nijmegen, Netherlands-based global drug discovery company, acquired Exemplify BioPharma, a Cranbury, NJ-based provider of integrated drug development services.
The amount of the deal was not disclosed.
With the acquisition, Symeres will further strengthen its strategic foothold in the US.
Led by CEO Yadan Chen, Exemplify BioPharma is a provider of integrated small molecule Chemistry Manufacturing and Controls services to pharmaceutical and biotech partners. The company offers consultancy services in Process Chemistry, Analytical Chemistry, and Formulation Development for a successful transition of programs from late-stage optimization through candidate selection to first-in-human. Exemplify employs 20 people, of which the majority are Ph.D-level scientists.
Led by CEO Eelco Ebbers, Symeres is a mid-sized transatlantic Contract Research Organization for drug discovery and development needs, with around 600 employees operating from 7 sites in the Netherlands, the Czech Republic, Finland, and the US. The company offers solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API.
Exemplify BioPharma is Symeres’ second acquisition in the US this year, following the acquisition of Organix Inc., an organic chemistry services provider based in the Boston area specialized in lipids addressing the mRNA therapeutics and vaccines market.
FinSMEs
26/10/2022